Carl Fichtenbaum
Vice Chair, Clinical Research · University of Cincinnati Medical Center Inc.
Credentials: · · · ·
History
PresentClinical Research · University of Cincinnati Medical Center Inc.
1990–1991
National Institute of Drug Abuse
1985–1988- 1977–1981
University of Missouri (Biology
Research
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
New England Journal of Medicine · 2021 · 495 citations
Clinical Infectious Diseases · 2003 · 454 citations
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
New England Journal of Medicine · 2023 · 451 citations
70 papers
- MZ
63 papers
63 papers
63 papers
58 papers
55 papers
47 papers · 33 as a resident
- ML
46 papers
Grants
- 2007–2013
University of Cincinnati AIDS Clinical Trials Unit- UC ACTU
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $7.1M · University of Cincinnati
- 2007–2013
University of Cincinnati AIDS Clinical Trials Unit- UC ACTU
National Institute of Allergy and Infectious Diseases · UM1
Contact PI · $3.2M · University of Cincinnati
- 2003–2004
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $24.3K · Cincinnati Childrens Hosp Med Ctr
- 1996–2000
Epidemiology and Outcome of Stds in Drug Users
National Institute on Drug Abuse · R01
Contact PI · $406.7K · University of Cincinnati
Clinical trials
- 2019–2024
CCR5-modified CD4+ T Cells for HIV Infection
Principal investigator · Completed · Phase 1, Phase 2
University of Cincinnati
- 2009–2010
Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study
Principal investigator · Completed · Phase 1, Phase 2
University of Cincinnati
- 2006–2008
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
Principal investigator · Terminated · Phase 3
Immtech Pharmaceuticals, Inc
- 2005–2010
Principal investigator · Completed · Phase 4
University of Cincinnati